Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell Clinical Trial

Official title:

A Phase 2, Open Label Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K Dual δ/γ Inhibitor, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04204057
• Other study ID #: RP6530-1901
• Status: Completed
• Phase: Phase 2
• Start date: November 28, 2019
• Est. completion date: October 2, 2020

Study information

• Verified date: July 2021
• Source: Rhizen Pharmaceuticals SA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The trial is a Phase II, open label, Simon's two stage study design to evaluate the efficacy and safety of Tenalisib in patients with CLL who have relapsed or are refractory after at least one prior therapy.

Description:

Tenalisib is a highly specific and orally available dual PI3K δ/γ inhibitor. Pre-clinical experiments demonstrated that Tenalisib is highly effective in killing primary CLL cells in vitro. A Phase II study is planned to evaluate the efficacy and safety of Tenalisib in patients with relapsed/refractory CLL.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: October 2, 2020
• Est. primary completion date: October 2, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with diagnosis of B-cell CLL

2. Disease status defined as refractory to or relapsed after at least one prior therapy.

3. Presence of measurable lymphadenopathy presence of > 1 nodal lesion

4. ECOG performance status = 2.

5. Adequate bone marrow, liver, and renal function

Exclusion Criteria:

1. Richter's (large cell) transformation, or PLL transformation.

2. Cancer therapy/ any cancer investigational drug within 3 weeks (21 days) or 5 half-lives (whichever is shorter).

3. Prior exposure to drug that inhibits PI3K

4. Patient with ASCT/Allo-SCT receiving treatment for active GVHD.

5. Ongoing severe systemic bacterial, fungal or viral infection.

6. Central nervous system (CNS) involvement of leukemia or lymphoma.

7. Ongoing immunosuppressive therapy including systemic corticosteroids.

8. Known history of severe liver injury as judge by investigator.

9. Any severe and/or uncontrolled medical conditions or other conditions that could affect patient participation

10. Women who are pregnant or lactating.

11. Known seropositive requiring anti-viral therapy for i. human immunodeficiency virus (HIV) infection. ii. hepatitis B virus (HBV) infection iii. hepatitis c virus (HCV) infection iv. active CMV infection

-

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid

Intervention

Drug:
• Tenalisib
Tenalisib 800 mg BID, Orally

Locations

Country	Name	City	State
Bulgaria	University Multiprofile Hospital for Active Treatment "Dr Georgi Stranski" Ltd.,	Pleven
Bulgaria	University Multiprofile Hospital for Active Treatment "Sv Ivan Rilski" Ltd	Sofia
Georgia	Ltd. M.Zodelava Hematology Centre	Tbilisi
Georgia	Medivest - Institute of Hematology and Transfusiology	Tbilisi
Poland	Silesian Healthy Blood Clinic Grosicki, Grosicka Sp.J.	Chorzow
Poland	Voivodship Multi-Specialist Center for Oncology and Traumatology M. Copernicus	Lódz

Sponsors (1)

Lead Sponsor	Collaborator
Rhizen Pharmaceuticals SA

Countries where clinical trial is conducted

Bulgaria,  Georgia,  Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate (ORR)	Per Response Evaluation Criteria as defined by iwCLL guideline for CLL: Complete Response (CR), all parameters should be regressed to normal (lymph nodes = 1.5 cm; spleen size <13 cm; liver size normal; no constitutional symptoms; circulating lymphocyte count normal; platelet count = 100 x 109 /L; Hemoglobin = 11.0 g/dL). For partial response, at least two of the parameters (lymph nodes, liver and/or spleen size, constitutional symptoms, circulating lymphocyte count) and one parameter (platelet count, hemoglobin) need to improve if previously abnormal; Overall Response (OR) = CR + PR."	7 Months
Primary	Duration of Response (DoR)	Duration of response (DOR): DOR is defined as the interval from the first documentation of CR/PR to the first documentation of definitive disease progression or death from any cause.; Progression disease is defined using iwCLL criteria as at least one of the criteria of parameters (i.e., lymph nodes increase = 50% from baseline or from response; liver and/or spleen size increase = 50% from baseline or from response; any constitutional symptoms; circulating lymphocyte count increase = 50% over baseline) or criteria of parameters (i.e., platelet count decrease of = 50% over baseline secondary to CLL; hemoglobin decrease of = 50% over baseline secondary to CLL) should be met.	7 Months
Secondary	Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE Criteria v5.0	Summary of Treatment-Emergent Adverse Events-(Causality All). Patients will be monitored for adverse events and both related and as well as non-related adverse events will be captured during the study. All adverse events (irrespective of causality) will be reported.	7 Months
Secondary	Progression Free Survival (PFS)	Progression-free survival (PFS): PFS is defined as the interval from first dose to first documentation of definitive disease progression or death from any cause.	7 months